Medical specialists from Australia tagged as investigators in clinical trials studying Cholangiocarcinoma

Total 5 results

Amy Body
Seen in:
- Victoria, Clayton, Monash Medical Center
Trials:
- NCT04801095 (Principal Investigator)
Conditions:
Hao-Wen Sim
Seen in:
- New South Wales, Darlinghurst, St Vincent's Public Hospital
- New South Wales, Sydney, St Vincent's Hospital Sydney
- Sydney, St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
Trials:
- NCT03763604 (Principal Investigator)
- NCT04879368 (Principal Investigator)
- NCT05727176 (Principal Investigator)
Conditions:
Niall Tebbutt, FRACP
Seen in:
- Victoria, Melbourne, Austin Health
Trials:
- NCT00973713 (Principal Investigator)
Conditions:
- Cholangiocarcinoma
Sanjeev Gill
Seen in:
- Victoria, Melbourne, Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center
Trials:
- NCT05727176 (Principal Investigator)
Conditions:
Timothy Price
Seen in:
- South Australia, Adelaide, Queen Elizabeth Hospital / Lyell McEwin Centre
- South Australia, Adelaide, The Queen Elizabeth Hospital
- South Australia, Woodville South, Queen Elizabeth Hospital
- South Australia, Woodville South, The Queen Elizabeth Hospital
Trials:
- NCT04879368 (Principal Investigator)
- NCT05042128 (Principal Investigator)
- NCT05712356 (Principal Investigator)
Conditions:

Clinical Trials on Cholangiocarcinoma

Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma

United States
RedHill Biopharma Limited

Completed

A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic

United States
RedHill Biopharma Limited

Available

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Completed

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Cholangiocarcinoma

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8

United States
AIO-Studien-gGmbH
Servier

Completed

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC)

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma Advanced

Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States

Medical specialists from Australia tagged as investigators in clinical trials studying Cholangiocarcinoma

Clinical Trials on Cholangiocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations